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Epithelial-mesenchymal interactions regulate normal gut epithelial homeostasis and have a putative role in 
inflammatory bowel disease and colon cancer pathogenesis. Epimorphin is a mesenchymal and myofibroblast 
protein with antiproliferative, promorphogenic effects in intestinal epithelium. We previously showed that 
deletion of epimorphin partially protects mice from acute colitis, associated with an increase in crypt cell prolif-
eration. Here we explored the potential therapeutic utility of modulating epimorphin expression by examining 
the effects of epimorphin deletion on chronic inflammation–associated colon carcinogenesis using the azoxy-
methane/dextran sodium sulfate (AOM/DSS) model. We found that mice in which epimorphin expression was 
absent had a marked reduction in incidence and extent of colonic dysplasia. Furthermore, epimorphin dele-
tion in myofibroblasts altered the morphology and growth of cocultured epithelial cells. Loss of epimorphin 
affected secretion of soluble mesenchymal regulators of the stem cell niche such as Chordin. Importantly, IL-6 
secretion from LPS-treated epimorphin-deficient myofibroblasts was completely inhibited, and stromal IL-6 
expression was reduced in vivo. Taken together, these data show that epimorphin deletion inhibits chronic 
inflammation–associated colon carcinogenesis in mice, likely as a result of increased epithelial repair, decreased 
myofibroblast IL-6 secretion, and diminished IL-6–induced inflammation. Furthermore, we believe that modu-
lation of epimorphin expression may have therapeutic benefits in appropriate clinical settings.
*OUSPEVDUJPO
Dynamic and reciprocal epithelial-mesenchymal interactions play a 
critical role in intestinal morphogenesis, maintenance of the steady 
state between epithelial proliferation and differentiation along the 
crypt villus axis (1), and epithelial carcinogenesis (2, 3). The gut 
mesenchyme, which gives rise to subepithelial myofibroblasts as 
well as other stromal components (4), supports the normal growth 
and development of the endoderm and directs regional specific-
ity in the gut (1, 5, 6). Mesenchymal stem cells (MSCs) likely play 
an important role in epithelial injury and repair (7–9). Intestinal 
subepithelial myofibroblasts are located in the lamina propria and 
are directly adjacent to the crypts, which contain epithelial stem 
and proliferating progenitor cells. Myofibroblasts secrete a variety 
of signaling molecules, growth factors, and soluble mediators of 
inflammation. These cells play a critical role in epithelial restitution 
and wound repair and contribute to modulation of the immune 
response, tissue fibrosis, and colonic tumorigenesis (3, 8, 10).
Epimorphin is a mesenchymal/myofibroblast protein that is a 
member of the syntaxin family of membrane bound, intracellular 
vesicle docking proteins known as t-SNAREs (11–13). Monomer-
ic epimorphin (also referred to as syntaxin 2) has been detected 
intracellularly as a component of the SNARE machinery that tar-
gets secretory vesicles to the plasma membrane (13, 14). Studies of 
lung, skin, and mammary epithelium suggest a role for myofibro-
blast/stromal epimorphin in the formation of luminal, ductular, 
or branching structures during ontogeny (11, 15, 16). The molecu-
lar basis of the biologic function of epimorphin is complex, and 
investigations of its role in morphogenesis of the mammary epi-
thelium have suggested that epimorphin has distinct, cell-specific 
extra- and intracellular roles (12, 16, 17).
We have previously shown that epimorphin is expressed by intesti-
nal subepithelial myofibroblasts and that it exerts antiproliferative, 
promorphogenetic effects on adjacent small intestinal epithelium 
(18). To precisely define its in vivo role, we generated epimorphin-
deleted (Epim–/–) mice and showed that epimorphin regulates basal 
proliferation of small intestinal, but not colonic, epithelium (19). 
Neonatal Epim–/– mice have increased small bowel crypt depth, 
crypt cell proliferation, and crypt fission. The consequences of epi-
morphin deletion are mediated, at least in part, by effects on bone 
morphogenetic protein (BMP) and Wnt–β-catenin pathways (18, 
19). Deletion of epimorphin partially protected the colon from 
injury in a dextran sodium sulfate–induced (DSS-induced) colitis 
model, associated with a marked increase in crypt cell proliferation 
(19). These studies suggested that effects of epimorphin deletion 
on downstream effector pathways may have potential therapeutic 
benefit for human inflammatory bowel disease (IBD). A critical 
complication of chronic gut inflammation from IBD is a mark-
edly increased risk of colon cancer (20). To determine the long-term 
effect of epimorphin deletion in colitis-associated colon cancer, here 
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we examined the susceptibility of Epim–/– mice to chronic inflam-
mation–induced carcinogenesis using the azoxymethane/DSS 
(AOM/DSS) model. Epimorphin deletion resulted in an increase 
in colonic crypt cell proliferation, yet markedly reduced dysplastic 
tumor burden. Absence of epimorphin profoundly affected myo-
fibroblast secretory function and response to LPS, resulting in 
altered myofibroblast interactions with epithelium, in an in vitro 
coculture model. In vivo analysis revealed decreased BMP signaling 
and reduced IL-6 expression in AOM/DSS-treated Epim–/– colons. 
Our results suggest that the myofibroblast plays an important role 
in inflammation-induced colon cancer and that strategies to alter 
myofibroblast function may provide novel therapeutic avenues for 
the treatment of colitis and prevention of colitis-associated cancer.
3FTVMUT
Epimorphin deletion markedly reduces dysplasia and polyposis in the 
AOM/DSS model of colon carcinogenesis. To determine the effects of 
epimorphin deletion on inflammation-induced dysplasia and car-
cinogenesis, we treated congenic Epim–/– mice (C57BL/6J) and WT 
C57BL/6J mice with AOM (13.5. mg/kg) followed by 3 5-day cycles 
of 2.5%–3.0% DSS (Supplemental Figure 1; supplemental material 
available online with this article; doi:10.1172/JCI40676DS1). This 
regimen was chosen based on our pilot studies (see Methods) that 
showed that lower doses of AOM and DSS (21, 22) were ineffective 
in inducing dysplasia in WT and Epim–/– mice. The higher doses 
resulted in dysplasia in 11 of 11 WT mice and 10 of 11 Epim–/– 
mice, with a mortality rate of 50% (11 of 22) of WT mice and 35% 
(6 of 17) of Epim–/– mice (P = NS).
Induction of colitis in mice results in body weight loss. The per-
cent body weight loss in Epim–/– mice was significantly reduced 
compared with WT mice after the completion of the second of 
3 DSS treatments (Supplemental Figure 2).
The pattern and extent of polyposis was evaluated in all mice 
that survived the regimen (11 Epim–/– and 11 WT). Epim–/– mice 
had a markedly decreased tumor load, with a decrease in the per-
centage of total colonic surface area grossly replaced by tumor, 
compared with WT mice (WT, 14.45%; Epim–/–, 4.96%; P = 0.01; 
Figure 1A). Whereas all WT mice had polyps and dysplasia, 1 of 11 
Epim–/– mice had no evidence of polyps and dysplasia. Polyposis 
in the WT mice was characterized grossly by multiple coalescing 
tumors with very small areas of intervening normal mucosa. In 
contrast, the Epim–/– polyposis phenotype consisted of scattered 
lesions throughout the descending colon, separated by wide areas 
of normal mucosa (Figure 1, B and C). Histological analysis by H&E 
staining revealed that in addition to gross polyposis, there were 
also areas of “flat” dysplastic change. The diameter of each area 
of dysplasia per field of vision was measured by ocular microm-
eter. In the WT mouse colon, the average diameter of the dysplas-
tic area was 2,040 μm compared with 1,075 μm in Epim–/– mice 
(P < 0.01; Figure 1D). In addition, there was a decrease in the num-
ber of dysplastic lesions per field of vision in Epim–/– mice (14.8%; 
n = 11) compared with WT mice (32.6%; n = 11; P = 0.041; Figure 
1E). 1 of 11 Epim–/– mice had dysplasia in the ascending colon in 
addition to the descending colon; 4 of 11 WT mice had dysplasia 
in the ascending colon or cecum in addition to the descending 
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plasia comparing WT with Epim–/– mice (Figure 1, F and G). In 
addition, the pattern of β-catenin immunostaining was similar, 
with nuclear accumulation only in areas of high-grade dysplasia 
(Supplemental Figure 3). Cyclin D1 expression was also similar 
(data not shown).
After brief exposure to DSS, Epim–/– mice exhibited a marked 
increase in colonic crypt cell proliferation (19). AOM/DSS-treated 
mice were injected with 5-BrdU 90 minutes prior to sacrifice, and 
the labeling index was calculated in nondysplastic areas of the 
cecum and the proximal and distal colon (Figure 2). There was 
a significant increase in crypt cell proliferation in Epim–/– versus 
WT mice in the cecum (Epim–/–, 14.64%; WT, 9.11%; P < 0.005) and 
distal colon (Epim–/–, 16.64%; WT, 11.15%; P = 0.051), with a trend 
toward an increase in the proximal colon. However, in dysplastic 
areas of descending colon, there were no differences in cellular 
proliferation per unit surface area (data not shown).
Areas of dysplastic and normal epithelium were evaluated for 
apoptotic rate. There was no change in apoptosis in Epim–/– com-
pared with WT mice, although effects on apoptosis at an earlier 
stage in the disease process cannot be ruled out, since tissues were 
analyzed at the end of the AOM/DSS treatment period.
Epimorphin deletion in myofibroblasts alters the morphology and growth 
of cocultured Caco-2 cells. Epimorphin is abundantly expressed in 
intestinal myofibroblasts, a major source of epimorphin in the 
gut (19, 23). Immunohistochemical analysis of dysplastic colon 
revealed that epimorphin was expressed in stroma surrounding 
areas of dysplasia (Supplemental Figure 4).
To elucidate the mechanisms underlying the protection from epi-
thelial dysplasia in Epim–/– mice, primary cultures of colonic myofi-
broblasts from Epim–/– and WT mice were established as described 
previously (see Methods and ref. 24). Myofibroblast phenotype 
was confirmed by immunocytochemistry showing robust expres-
sion of α-SMA and vimentin (Figure 3, A–D), minimal desmin 
expression, and absence of expression of epithelial cytokeratin 19 
(data not shown), consistent with a colonic myofibroblast pheno-
type (3) and similar to well-characterized small bowel myofibro-
blasts (24). Colonic myofibroblasts from WT mice also expressed 
epimorphin and α-SMA, as determined by immunoblot (Figure 
3E). As expected, myofibroblasts from Epim–/– mice did not express 
epimorphin, but produced abundant α-SMA.
To examine the effects of myofibroblasts on the morphology, 
proliferation, and differentiation of epithelium, we cocultured 
myofibroblasts with Caco-2 cells (Figure 4). Caco-2 cells have been 
routinely used in coculture models, as they adhere well to myo-
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and provide reproducible colony morphology (1, 18). Caco-2 cells 
formed larger colonies on Epim–/– colon myofibroblasts compared 
with Caco-2 colonies grown on WT myofibroblasts, which were 
small and compact (Epim–/–, 128 μm colony diameter; WT, 76 μm 
colony diameter; P < 0.05; Figure 4, A–C). Morphologic analysis 
showed that Caco-2 cells seeded on WT myofibroblasts formed 
multiple discrete, spherical, compact, and pseudostratified colo-
nies. In contrast, Epim–/– myofibroblasts formed an epithelial 
monolayer with only occasional small foci of pseudostratified 
epithelium (Figure 4, D and E). To eliminate the possibility that 
the morphologic differences were due to differences in adhesion 
of Caco-2 cells to myofibroblasts, the number of adherent versus 
floating cells was quantified from media of Epim–/– and WT myo-
fibroblast–Caco-2 cocultures. No differences were noted at 24 or 
72 hours after plating (data not shown).
Epimorphin deletion alters colonic myofibroblast expression of 
paracrine factors including components of BMP, Hedgehog (Hh), 
and Wnt signaling pathways. To further elucidate the molecular 
basis for the differences in dysplasia in Epim–/– compared with WT 
colon, gene expression profiling of Epim–/– versus WT colon myo-
fibroblasts was performed using Agilent microarrays. The total 
number of genes induced or inhibited greater than 2-fold as a con-
sequence of epimorphin deletion was 2,552 and 3,327, respectively. 
Because of the large number of genes that exhibited changes in 
expression, we focused on confirming changes in expression in 
gene families that encode stromal factors involved in the regula-
tion of colonic epithelial proliferation. These included members of 
the TGF-β superfamily including the BMP, Hh, and Wnt families 
(Table 1). Changes in expression were confirmed by quantitative 
real-time polymerase RT-PCR (qRT-PCR; Supplemental Methods; 
n = 3 independent experiments). Additional key candidate genes 
for each signaling pathway were also evaluated by qRT-PCR. Of 
the TGF-β superfamily members, BMP4 expression was increased 
2.1-fold in Epim–/– compared with WT myofibroblasts. Marked 
alterations in expression of BMP inhibitors was noted, including 
Chordin-1 (68-fold increase), Follistatin (10-fold decrease), and 
Noggin (64-fold decrease). Gremlin-2 expression was unchanged. 
Analysis of the Hh signaling pathway showed that expression of 
Hh family members including Hh-interacting protein (Hhip), 
Cyclin BI, Patched-2, and Gli-3 were all decreased. In the Wnt fam-
ily, expression of the Wnt inhibitors Dkk2, Dkk3, and Sfrp4 was 
increased (2.9- to 6.2-fold); with a 1.5-fold decrease in Sfrp1.
Because the fold change in expression of the BMP inhibitors was 
widely divergent in Epim–/– compared with WT myofibroblasts, we 
examined the relative expression levels of BMP4 and BMP inhibi-
tors in WT and Epim–/– myofibroblasts (Figure 5) to determine 
which were the most abundantly expressed, and therefore might 
be the most physiologically relevant. There was abundant BMP4, 
Chordin-1, Follistatin, and Gremlin-2 mRNA expression in WT 
and Epim–/– myofibroblasts, but significantly lower basal Noggin 
expression compared with Chordin and BMP4 (P < 0.05; Figure 5). 
The changes in expression were highest for Chordin (68-fold 
increase) and Noggin (64-fold decrease; P < 0.05).
Epimorphin deletion results in increased production and secretion of 
members of the BMP pathway. BMP4 and Chordin protein expres-
sion in cell lysate and media was quantified by ELISA (Supple-
mental Methods). Chordin expression was significantly increased 
in Epim–/– compared with WT colon myofibroblasts (Figure 6A), 
and there was a 10-fold increase in Chordin protein secretion from 
Epim–/– versus WT colon myofibroblasts (Figure 6B; P < 0.05). In 
addition, BMP4 protein expression was higher in Epim–/– myofi-
broblasts compared with WT (P < 0.05), and BMP4 secretion from 
unstimulated Epim–/– myofibroblasts was 2-fold higher than WT, 
although the difference was not statistically significant (Epim–/–, 
79.8 pg/ml; WT, 39.5 pg/ml; P = 0.058; Figure 6, C and D).
To determine whether the effect of myofibroblast epimorphin 
deletion on Caco-2 colony morphology is mediated by Chordin, 
Epim–/– and WT myofibroblasts were cocultured with Caco-2 
cells in the presence and absence of Chordin as described previ-
ously (25), and Caco-2 colony diameter was measured. Addition 
of Chordin to WT cocultures increased Caco-2 colony size from 
80 to 205 μm (P < 0.05; Figure 7). Observation by inverted phase 
microscopy indicated that addition of Chordin reproduced the 
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blasts, with a predominance of epithelial monolayers in the Chor-
din-treated cocultures (data not shown). As expected, the size of 
Caco-2 colonies grown on Epim–/– myofibroblasts was unchanged 
in the presence of additional exogenous Chordin (P = NS). These 
results suggested that increased Chordin secretion was at least 
partly responsible for the effect of epimorphin deletion on Caco-2 
colony morphology.
To correlate these in vitro findings in vivo, we examined the 
expression of BMP2 and BMP4 as well as the primary end tar-
get of BMP signaling, p-Smad1/5/8. Sections of dysplastic colon 
from WT and Epim–/– myofibroblasts were incubated with an anti-
BMP2/4 antibody that detects BMP2 expression in colonic epithe-
lial cells (26, 27) and BMP4 expression in stroma (27–29). BMP2 
and BMP4 were expressed in WT and Epim–/– colon; in a subset of 
Epim–/– colons, a small increase in epithelial and stromal expres-
sion was noted (Supplemental Figure 5).
To determine the net effect of epimorphin deletion on BMP 
signaling in vivo, we examined p-Smad1/5/8 expression by 
immunohistochemical analysis of AOM/DSS-treated Epim–/– and 
WT colons (Figure 8). There was a marked decrease in p-Smad1/5/8 
immunostaining in both normal, nondysplastic Epim–/– colon 
(Figure 8, A and B) and dysplastic descending colon and rectal 
epithelium (Figure 8, C–F) compared with AOM/DSS-treated WT 
colon. These findings further suggest that epimorphin deletion in 
myofibroblasts results in net BMP inhibition.
Epimorphin deletion blunts the colonic myofibroblast response to LPS. 
Cytokine release plays a key role in tissue damage and the inflam-
matory response in IBD (30). To determine cytokine expression 
and secretory function in WT and Epim–/– myofibroblasts, cells 
were treated with LPS for 24 hours to mimic the colitis-induced 
inflammatory milieu. Expression of inflammatory mediators 
upregulated in acute DSS colitis (TNF-α, IL-6, IFN-γ) with key 
roles in colitis-associated colon carcinogenesis (31, 32) was evalu-
ated by qRT-PCR. In response to LPS, IL-6 expression increased in 
WT and Epim–/– myofibroblasts compared with unstimulated myo-
fibroblasts (P < 0.05; Figure 9A). After exposure to LPS, IL-6 mRNA 
expression in Epim–/– myofibroblasts was decreased compared with 
WT cells. However, IL-6 protein expression was increased in LPS-
stimulated Epim–/– myofibroblasts compared with unstimulated 
Epim–/– cells, at levels exceeding those of LPS-stimulated WT cells 
(Figure 9B). Despite abundant protein expression, Epim–/– myo-
fibroblasts did not secrete IL-6 into the media, unlike WT cells 
(Figure 9C). The profound decrease in IL-6 secretion in response 
to LPS was not due to absence or downregulation of TLR expres-
sion. Myofibroblasts responded to LPS by increasing IL-6 mRNA 
and protein in both Epim–/– and WT myofibroblasts. In addition, 
TLR4 mRNA was expressed in myofibroblasts, and TLR4 mRNA 
levels were increased greater than 2-fold in Epim–/– compared with 
WT cells (data not shown).
IFN-γ expression was very low in both Epim–/– and WT colon 
myofibroblasts and was not altered in response to LPS (data not 
shown). TNF-α mRNA expression in WT and Epim–/– myofibro-
blasts was barely detectable, and was more than 10-fold lower than 
IL-6 expression. TNF-α protein was not detected in cell lysates, nor 
was it detectable in secreted form upon LPS stimulation in either 
WT or Epim–/– myofibroblasts (data not shown).
To correlate these in vitro findings in vivo, we performed 
immunohistochemical analysis of IL-6 expression in AOM/DSS-
treated Epim–/– and WT colon (Figure 10). IL-6 expression in WT 
dysplastic colon (Figure 10A) and in normal nondysplastic areas 
(Figure 10, C and E) was strongest in the stroma, with weak but 
detectable expression in the epithelium (consistent with previ-
ously reported IL-6 expression patterns; ref. 31). In contrast, 
in dysplastic (Figure 10B) and adjacent nondysplastic colonic 
5BCMF
Effects of epimorphin deletion on expression of selected mem-
bers of the BMP, Hh, and Wnt pathways
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mucosa of AOM/DSS-treated Epim–/– mice (Figure 10, D and 
F), stromal IL-6 expression was markedly diminished compared 
with WT. Despite the decrease in stromal expression, pericryptal 
cells at the base of the crypts in Epim–/– mice showed expression 
of IL-6 (Figure 10F), consistent with their ability to synthesize 
but not secrete IL-6 (Figure 9C).
Serum levels of IL-6 and TNF-α were measured by ELISA in 
AOM/DSS-treated Epim–/– and WT mice, and no significant dif-
ferences were found (data not shown, n = 4 mice per group). Serum 
concentrations were measured in individual mice, and there was 
no correlation between tumor burden and serum cytokine levels. 
These results suggested that epimorphin deletion may not block 
IL-6 secretion from other cell types, e.g., from myeloid cells such 
as macrophages (which also express epimorphin; ref. 33) and den-
dritic cells, the 2 major cellular sources of elevated IL-6 levels in 
chronic inflammation–associated carcinogenesis (31). To evaluate 
whether epimorphin deletion inhibits IL-6 secretion from other 
cell types, we examined the effect of epimorphin deletion on resi-
dent peritoneal macrophages, which are reflective of the intesti-
nal environment and well-described in the colitis model (34, 35), 
and on bone marrow–derived dendritic cells. Resident peritoneal 
macrophages were cultured as described previously (35, 36), and 
supernatants were collected for IL-6 assay. Epimorphin deletion 
significantly diminished, but did not completely block, secretion 
of IL-6 from resident peritoneal macrophages (689 pg/ml to 272 
pg/ml; P < 0.05; Supplemental Figure 6). We then evaluated the 
effect of epimorphin deletion on cultured bone marrow–derived 
dendritic cells. Because this population does not secrete measur-
able IL-6 at baseline, cells were treated with LPS for 24 hours, 
and IL-6 secretion was quantified. Epimorphin deletion did not 
change IL-6 secretion in response to LPS, which increased in both 
WT and Epim–/– bone marrow–derived dendritic cells (data not 
shown). These data suggest that epimorphin deletion reduces local 
IL-6 production from myofibroblasts, and, to a lesser extent, from 
macrophages, which are uniquely located adjacent to epithelium 
and the stem cell niche (9).
To rule out the possibility that compensatory changes in other 
syntaxins resulted in the altered secretory patterns in Epim–/– myo-
fibroblasts, we examined expression of syntaxins 1a, 3, and 4, which 
have the highest percentage homology with epimorphin, and syn-
taxins 5 and 6, which are also expressed in myofibroblasts (ref. 
37 and Supplemental Figure 7). No differences in mRNA expres-
sion were noted except for absence of epimorphin, as expected, 
in Epim–/– myofibroblasts.
To further evaluate the altered secretory patterns in Epim–/– myo-
fibroblasts, electron microscopy was performed to analyze the 
ultrastructural morphology of Epim–/– and WT myofibroblasts 
(Figure 11). Parameters included nuclear to cytoplasmic ratios, 
nuclear membrane regularity and/or roundness, cytoplasmic 
membrane complexity, length and state of distention of the rough 
endoplasmic reticulum (RER), and mitochondria. There was an 
increase in long parallel stacks of RER in Epim–/– cells (Figure 11, 
A and B). In addition, the short stacks of RER were significantly 
more dilated in Epim–/– myofibroblasts (Figure 11C). Dilation of 
RER is associated with increased accumulation of protein (38, 39), 
consistent with our findings that synthesis and secretion of IL-6 
and a subset of BMP inhibitors were markedly altered by epimor-
phin deletion. There were no differences in the other morphologic 
parameters. Because these morphological findings were suggestive 
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unsliced (Xbp-1u), Xbp-1 sliced (Xbp-1s), Atf4, and Grp78 were 
evaluated. Epimorphin deletion increased Xbp-1u, Xbp-1s, and 
Atf4 (1.9-, 2.7-, and 1.7-fold, respectively; P < 0.05), whereas Grp78 
remained unchanged (Figure 11D).
Epimorphin deletion alters Hh signaling. Hh ligands produced by gut 
epithelial cells act on receptors located on mesenchymal cells to acti-
vate downstream stromal target genes (41, 42). Hhip, Gli-1, Gli-2, 
Gli-3, Patched 1 (Ptc-1), and Ptc-2 are stromal targets of Hh signals, 
and Hh signaling activity is best reflected by measuring Gli1, Ptc-1, 
and Hhip mRNA levels (42, 43). Several Hh targets are expressed by 
both WT and Epim–/– colon myofibroblasts, and mRNA levels of a 
subset of these were decreased in Epim–/– compared with WT myo-
fibroblasts (Table 1), including a marked decrease in expression of 
Hhip, which inhibits Hh signaling and reflects pathway signaling 
activity. Because Hh ligands are expressed only in epithelial cells, 
cultured myofibroblasts presumably do not receive Hh signals, and 
signaling activity is low. To determine the physiologic significance 
of the decreased expression of several Hh targets in Epim–/– myo-
fibroblasts, myofibroblasts were incubated with recombinant 
sonic hedgehog (Shh) to determine whether there is also a blunted 
response to Hh signals. (Ihh and Shh are identical with respect to 
receptor binding and target gene activation; ref. 44). Expression 
of Hhip increased 3.5-fold (P < 0.05), Gli-1 increased 6.13-fold 
(P < 0.05), and Ptc-1 increased 2.8-fold (P = 0.07) in WT myofi-
broblasts treated with Shh. Epim–/– colon myofibroblasts treated 
with Shh had increased expression of Gli1 only (2.3-fold; P < 0.01); 
however, absolute levels of Gli1 remained 3.7-fold less than in WT 
(P < 0.005). Treatment with Shh did not induce Hhip and Ptc-1 
expression in Epim–/– myofibroblasts (Figure 12).
%JTDVTTJPO
Deletion of epimorphin reduced the incidence and extent of dys-
plasia in the AOM/DSS model of inflammation-induced colon 
carcinogenesis. This protection from dysplasia was associated with 
increased crypt cell proliferation in adjacent nondysplastic Epim–/– 
epithelium. Epimorphin deletion also affected myofibroblast-epi-
thelial interactions in vitro: WT myofibroblasts cocultured with 
epithelial Caco-2 cells exhibited small, compact Caco-2 colony 
morphology with a pseudostratified epithelium; in contrast, Caco-
2 cells cocultured with Epim–/– myofibroblasts showed increased 
colony diameter and epithelial monolayer formation. Epimorphin 
deletion induced marked changes in expression and secretion of 
a subset of BMP inhibitors, resulting in a net decrease in colonic 
BMP signaling, as indicated by reduced p-Smad1/5/8 expression. 
The importance of BMP inhibition was further established by 
showing that addition of Chordin to WT myofibroblast–Caco-2 
epithelial cocultures recapitulated the growth and morphology of 
Caco-2 colonies cocultured with Epim–/– myofibroblasts. Epimor-
phin deletion also resulted in a profound decrease in LPS-stimulat-
ed myofibroblast secretion of the proinflammatory cytokine IL-6, 
with reduced IL-6 expression in AOM/DSS-treated Epim–/– colon. 
Electron microscopy of Epim–/– myofibroblasts depicted morpho-
logic changes in the RER consistent with the marked alteration in 
synthesis and secretion of IL-6 and Chordin.
Our data suggest that the mechanisms by which epimorphin 
deletion results in protection from dysplasia are complex, and 
likely include enhanced epithelial repair resulting from episodic 
increased crypt cell proliferation as well as reduced epithelial cell 
damage caused by decreased inflammation. These changes appear 
to be mediated, at least in part, by inhibition of BMP and IL-6 sig-
naling. In addition, because IL-6 has been postulated to regulate 
tumor stem cell proliferation, epimorphin deletion may also exert 
effects on tumorigenesis.
BMP, Wnt, Hh, and Notch signaling interplay in the stem cell 
niche to regulate intestinal crypt cell proliferation (29, 45–48). Our 
data showed that expression and secretion of a subset of soluble 
mesenchymal BMP pathway components were regulated by epi-
morphin deletion, resulting in decreased BMP signaling in vivo 
(Figure 8). BMPs and BMP inhibitors originate from the stroma 
and act on adjacent epithelium (27–29). Expression of these inhib-
itors is highest toward the base of the crypts, adjacent to the stem 
cell niche (49). BMPs inhibit crypt cell proliferation, presumably 
via effects on Wnt–β-catenin signaling mediated by the PTEN-
PI3K-Akt pathway (29), although the precise mechanisms are still 
being clarified (50). A balance between BMPs and BMP inhibitors 
is thought to play a role in maintaining normal basal levels of 
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The net effect of epimorphin deletion is inhibition of BMP sig-
naling in the epithelium, as indicated by decreased p-Smad1/5/8 
expression (Figure 8). This would be expected to lead to an increase 
in crypt cell proliferation, as shown in Figure 2. Although expres-
sion of a subset of BMP inhibitors is decreased in Epim–/– myofibro-
blasts (Figure 5), and BMP4 expression and secretion were increased 
(Figures 5 and 6), it is likely that Chordin’s inhibitory actions are 
locally dominant in the crypt due to its 10-fold increased secretion. 
Chordin’s key role is further supported by its effects in Epim–/– myo-
fibroblast cocultures (Figure 7). We postulate that in Epim–/– mice, 
BMP inhibition stimulates enhanced crypt cell proliferation early 
in the course of AOM/DSS-induced disease, resulting in enhanced 
epithelial repair and decreased tumorigenesis.
Our model appears to result in partial, but not complete, BMP 
inhibition, as indicated by persistent, albeit reduced, p-Smad1/5/8 
expression. Complete BMP inhibition might be expected to result 
in a tumorigenic phenotype, as in mice that have a nonfunctional 
BMP receptor BMPR1A (51), or in Noggin-overexpressing mice 
(27, 28), both of which result in a juvenile polyposis phenotype 
and markedly enhanced epithelial proliferation rate. Although 
BMP inhibition is likely to result in unopposed Wnt signaling, 
epimorphin deletion resulted in decreased dysplasia. We postulate 
that in our model, BMP inhibition results in enhanced epithelial 
repair and that this, in conjunction with markedly reduced IL-6 
secretion, leads to partial protection from dysplasia.
Epimorphin deletion completely blocked IL-6 secretion by myo-
fibroblasts, and in vivo analysis of IL-6 expression in Epim–/– and 
WT dysplasia in the AOM/DSS model demonstrates that epimor-
phin deletion results in diminished stromal IL-6 expression. We 
also showed that epimorphin deletion reduced IL-6 secretion by 
peritoneal macrophages, but not by bone marrow–derived den-
dritic cells. Reduced stromal IL-6 likely results in decreased epi-
thelial cell damage (38). In addition, IL-6 is active in the tumor 
stem cell niche (52); reduced secretion may also result in decreased 
proliferation of dysplastic premalignant cells, thus suggesting a 
direct effect on tumorigenesis (31, 52). Our data are consistent 
with studies from other laboratories (31, 32, 53) that have shown 
that IL-6 plays a key role in the pathogenesis of colitis-associated 
carcinogenesis. The pleiomorphic effects of epimorphin deletion 
on secretion of multiple factors, particularly IL-6, likely explains 
why the observed increase in colonic crypt cell proliferation did 
not result in larger tumors, as in other genetic models of chronic 
inflammation–associated carcinogenesis, such as the SOCS3-null 
mouse (32). It is likely that the end result of epimorphin deletion 
is a change in secretion of soluble factors that overall has beneficial 
effects, resulting in reduced dysplasia.
Wnt signaling is critically important in regulating normal crypt 
cell proliferation and is dysregulated in colon carcinogenesis. In 
colitis-associated neoplasia, Apc mutations are much less com-
mon compared with sporadic colon cancer and occur later in the 
disease (20, 54). Both epithelial and mesenchymal cells express 
Wnts (55), but the precise sources and regulation of Wnt secre-
tion are still being clarified. Expression of several Wnt inhibitors 
was upregulated in Epim–/– myofibroblasts. However, epimorphin 
deletion did not alter expression of nuclear β-catenin or cyclin D1 
in dysplastic tumors and did not affect the proportion of low- and 
high-grade dysplastic lesions. The significance of the change in 
expression of Wnt inhibitors is unclear from our studies, which 
evaluated Wnt target gene expression at an advanced stage of the 
disease process. Following Apc mutation, nuclear β-catenin sig-
naling becomes dysregulated, and changes in Wnt ligand expres-
sion may no longer affect downstream signaling; however, it is 
possible that enhanced secretion of Wnt inhibitors earlier in the 






















Downloaded on September  6, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/40676
SFTFBSDIBSUJDMF
 The Journal of Clinical Investigation   http://www.jci.org   Volume 120   Number 6   June 2010 
We have shown that the function of Epim–/– myofibroblasts was 
profoundly altered, resulting in marked changes in myofibroblast 
secretory function. These effects are likely due to epimorphin’s role 
as a syntaxin. These membrane-bound proteins have an intracellular, 
cytoplasmic orientation and are involved in trafficking of secretory 
vesicles. Our data suggest epimorphin deletion results in marked 
and specific alteration in secretory function, indicating that particu-
lar syntaxins may regulate the release of a subset of secreted pro-
teins. Altered secretory function was not caused by compensatory 
changes in expression of other syntaxins in Epim–/– myofibroblasts 
(Supplemental Figure 7) or in Epim–/– intestine (19). IL-6 secretion 
from WT myofibroblasts was stimulated in response to LPS, but 
completely blocked in Epim–/– myofibroblasts. This occurred despite 
an increase in IL-6 mRNA and protein production in both Epim–/– 
and WT cells, suggesting a profound alteration in the IL-6 secretory 
process. In contrast, Chordin and BMP4 secretion were increased. 
The consequences of epimorphin deletion may be pathway depen-
dent, and appear to differ in stimulated versus constitutive secretory 
processes. In the mammary gland, epimorphin is itself secreted (12, 
17). However, immunoblot of concentrated media from WT myo-
fibroblasts showed virtually no secretion of epimorphin, despite 
abundant cellular protein expression (data not shown).
Epim–/– myofibroblasts showed decreased expression of Hh target 
genes after exposure to Hh ligands compared with WT myofibro-
blasts. These data suggest that deletion of epimorphin also affects 
the myofibroblast’s ability to respond to soluble factors that signal 
to the mesenchyme. Unlike in other epithelial cancers, in which 
activated Hh signaling results in increased proliferation, active 
Hh signaling has been shown to inhibit crypt cell proliferation in 
the colon and small bowel (46). It is possible that this change in 
responsiveness to Hh signals contributes to enhanced crypt cell 
proliferation in the Epim–/– mice, but further studies are required 
to interrogate this complex pathway.
Overall, our data suggest that protection from dysplasia is likely 
mediated, at least in part, by changes in the function and secre-
tory profile of intestinal subepithelial myofibroblasts. Our results 
suggest potentially novel pathogenetic mechanisms of inflamma-
tion-induced colonic dysplasia, which may be relevant for patients 
with IBD. Our data suggest that the stromal environment, includ-
ing the myofibroblast, plays a significant role in inflammation-
induced dysplasia. Although stromal interactions with the epithe-
lium have been suggested to play a pathogenic role in colorectal 
carcinogenesis and inflammation-induced colon cancer, the epi-
morphin deletion mouse model is unique because myofibroblast 
secretory function has been altered. MSCs have been increasingly 
recognized to play an important role in wound repair in epithelial 
tissues (7, 8, 56). Whether the MSC or a more differentiated prog-
eny cell is responsible for cross-talk within the stem cell niche is 
unclear. Our studies suggest that the myofibroblast may be one of 
the MSC progeny that is active within the stem cell niche. These 
studies also suggest what we believe to be a novel therapeutic tar-
get for treatment of IBD and prevention of colorectal cancer, since 
modifying myofibroblast function appears to affect epithelial cell 
proliferation and the incidence and severity of dysplasia.
In summary, epimorphin deletion showed beneficial effects in 2 
colitis/injury models, the acute DSS-induced colitis model (19) and 
the AOM/DSS model of colitis-associated carcinogenesis, which 
suggests that modulating the function of this myofibroblast pro-
tein may have a therapeutic effect in the appropriate clinical set-
ting. Our results confirm the complexity of mesenchymal-epithelial 
interactions and suggest a role for myofibroblasts in colonic injury, 
repair, and carcinogenesis. We have shown that, in the AOM/DSS 
model, an intervention resulting in increased crypt cell prolifera-
tion may still have beneficial effects even in the long term. Thus, 
therapies that increase epithelial repair and crypt cell proliferation 
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chronic inflammatory disorder armamentarium. Since epimorphin 
is widely expressed in the stroma of other epithelial tissues, these 
data may have relevance to other inflammation-induced epithelial 
cancers, such as those in pancreas, esophagus, and skin.
.FUIPET
Animals. Epim–/– mice, with a global deletion of epimorphin, were generated 
as described previously (19), and C57BL/6J WT littermates or C57BL/6J 
mice purchased from Jackson Laboratory were used as controls. Mice pur-
chased from Jackson Laboratory were acclimated to the animal facility for 
3.5 weeks. Mice were housed in a 12-hour light/dark cycle with free access 
to food and water. Mice were fed a standard rodent chow diet (PicoLab 20; 
Purina). Age-matched 8- to 12-week-old Epim–/– mice and their WT lit-
termates were used in all experiments. All animal experimentation was 
approved by the Animal Studies Committee of Washington University 
School of Medicine.
AOM/DSS model for colitis-induced carcinogenesis. Congenic Epim–/– mice 
(on a C57BL/6J background; n = 17) and WT C57BL/6J mice (n = 22) were 
injected with AOM (13.5 mg/kg; Sigma-Aldrich) on day 0 (Supplemental 
Figure 1). On day 5, 3 cycles of DSS (2.5%, 3%, 3% in drinking water; 5 days/
cycle) were initiated, each separated by 15 days of vehicle control (water). 
This regimen was chosen based on pilot studies showing that a previously 
published lower-dose regimen (21, 22) of AOM (12.5 mg/kg) followed by 
3 cycles of 2.5%, 2.5%, 2% DSS in drinking water did not result in dysplasia 
in our mice. Mice were sacrificed 20 days after completion of the third DSS 
cycle, and tissues were placed into 10% formalin for histology. The presence 
and grade of dysplasia (low versus high grade) was evaluated as described 
previously (57). Apoptosis was evaluated by routine histologic methods on 
H&E-stained tissue (58). Serum was collected, and ELISA was performed 
per the manufacturers’ instructions for TNF-α, IFN-γ (BD Biosciences), 
and IL-6 (eBioscience).
Crypt cell proliferation. At 90 minutes prior to sacrifice, mice were injected 
intraperitoneally with 5-BrdU (8 g/l) and 5-fluorodeoxyuridine (0.8 g/l), 
total dose 120 mg/kg. 5-BrdU was detected with a monoclonal anti-BrdU 
antibody (Zymed Laboratories Inc.), and crypt cell proliferation was 
assessed as described previously (19). To correct for differences in crypt 
depth, labeling index was calculated as the number of 5-BrdU–positive cells 
per total crypt cell number (19). Crypt cell proliferation indices were also 
quantified separately in areas adjacent to ulcerations and were compared 
in WT and Epim–/– mice.
Quantification of polyposis and dysplasia. Grossly visible polyps were counted 
and diameters measured. Tumor area and total colon area were measured 
using Metaview software, and the percentage of tumor area per total colon 
area was calculated. Colons were divided into cecum, proximal, and distal 
colon, sectioned, and stained with H&E. The entire colon was analyzed for 
dysplasia by light microscopy (magnification, ×40; the presence of dysplasia 
was confirmed under higher-power magnification, ×100). The number of 
fields of vision was counted, and the percentage with dysplasia was calcu-
lated as the number of dysplastic segments per fields of vision. The diameter 
of dysplastic lesions was measured with Axiovision software (Zeiss).
Generation of Epim–/– and WT colon myofibroblast primary cultures. 3 Epim–/– and 
3 WT colon myofibroblast primary cultures were established as previously 
described (24, 59) from WT and Epim–/– 7- to 9-day-old mice. Briefly, colon 
from cecum to rectum was placed in HBSS (Invitrogen), washed briefly, trans-
ferred into fresh HBSS, and minced into 2- to 3-mm pieces. Tissue was washed 
8 times with HBSS by vigorous shaking, allowing for fragments of colon to 
sediment out; incubated with 300 U/ml collagenase XI (Sigma-Aldrich) and 
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with gentle shaking; and then centrifuged at low speed (4 g) for 10 minutes. 
Supernatant was discarded. The pellet, containing intact organoids with 
attached myofibroblasts, was transferred to a 1.7-ml tube, minced with scis-
sors, and washed 5 times in DMEM (Gibco, Invitrogen) with 2% sorbitol 
(Sigma-Aldrich) to eliminate isolated cells and then centrifuged 1–2 min-
utes at low speed. Cells were seeded in 6-well plates and cultured in DMEM 
with 10% FBS (US Biotechnologies Inc.), insulin (Sigma-Aldrich), transferrin 
(Roche), and gentamicin (Calbiochem EMD Chemicals), all 10 μg/ml, as well 
as 2 ng/ml EGF (Sigma-Aldrich). After 4 days, mesenchyme-derived cells were 
passaged to T25 flasks using 0.05% trypsin in 0.53 mM EDTA (Cellgro, Medi-
atech). Under these conditions, epithelial cells do not survive.
Caco-2 cell culture. The Caco-2 human colon cancer epithelial cell line was 
grown as described previously (18). Cell lines were passaged every 4–7 days.
RNA analysis by qRT-PCR. qRT-PCR was performed as described previ-
ously (19); see Supplemental Methods for details. SuperScript II Reverse 
Transcriptase (Invitrogen) was used for synthesis of cDNA. Real-time 
RT-PCR analysis using SYBR green PCR Master Mix (Applied Biosystems) 
was performed in an ABI Prism 7700 sequence detection system (Applied 
Biosystems). Primer sequences are listed in Supplemental Table 1.
Gene expression profiling. To determine the identity of putative myofibro-
blast morphogens, total RNA was prepared from Epim–/– and WT colon 
myofibroblasts between passages 6–9, cultured for 1 week. Total RNA 
from which probes were generated was prepared from a pool of 3 myofi-
broblast isolates for each. Probes were hybridized to Agilent microarrays 
as per the Genomics Core of the Digestive Diseases Research Core Center 
(DDRCC, Washington University School of Medicine). The data set was 
searched to identify putative epimorphin targets that exhibited greater 
than 2-fold increase or less than 0.5-fold decrease in expression between 
Epim–/– and WT colon myofibroblasts (GenePix 6.0 acquisition and analy-
sis software; ref. 18), focusing on members of the BMP/TGF-β, Wnt, and 
Hh families. Changes in expression of selected genes on microarray were 
all confirmed by qRT-PCR.
Immunocytochemistry. Primary cultures of colonic myofibroblasts and 
Caco-2 cell lines were grown on chamber slides (Nalge Nunc International) 
and fixed in 10% formalin (room temperature) for 10 minutes, permea-
bilized with ice-cold methanol, and stored at –20°C. After incubation in 
blocking solution containing 5% BSA and 3% milk in Tris buffer (20 mM 
Tris HCl; 150 mM NaCl, pH 7.4; and 0.05% Tween 30) for 60 minutes, slides 
were incubated with primary antibody diluted in blocking solution at 4°C 
overnight. To confirm the myofibroblast phenotype, rabbit polyclonal 
antibodies to α-SMA (ab5694, 1:200 dilution; Abcam); desmin (D8281, 
1:100 dilution; Sigma-Aldrich); cytokeratin 18 (1:100 dilution; Millipore 
Corp.); vimentin (V4630, 1:100 dilution; Sigma-Aldrich); were used. Sec-
ondary antibody labeled with fluorescein or Cy3 diluted in blocking solu-
tion was applied for 1 hour at room temperature. Cells were mounted in 
Vectashield Mounting Medium with DAPI and examined under a fluores-
cence microscope (Axioshop 2; Carl Zeiss Jena GmbH).
Immunohistochemical analyses. Epimorphin expression in WT colon was 
analyzed as described previously (19) using a polyclonal rabbit anti–syn-
taxin 2 antibody (1:500 dilution; Synaptic Systems) that was purified to 
remove cross-reactivity with other syntaxins, by preabsorption with total 
protein isolated from Epim–/– mouse intestine (1 μg antibody incubated 
with 50 μg protein). Epitope retrieval was with the Nuclear DECLOAKER 
reagent (BIOCARE) in a decloaking chamber. Primary antibody was 
applied overnight at 4°C. Antigen antibody complexes were detected with 
biotinylated goat anti-rabbit IgG (1:2,000 dilution) and donkey anti-goat 
IgG (1:2,000 dilution; Jackson ImmunoResearch Laboratories Inc.) and 
streptavidin–horseradish peroxidase with tyramide amplification, then 
developed in diaminobenzidine.
BMP2/BMP4 expression was detected as described previously (19) using 
a polyclonal goat anti-human BMP2/4 antibody (1:300 dilution; R&D Sys-
tems) that cross-reacts with mouse, and antigen retrieval with citraconic anhy-
dride. p-Smad1/5/8, nuclear β-catenin, and cyclin D1 expression was detect-
ed using a polyclonal rabbit anti–p-Smad1/5/8 (1:100 dilution; Millipore), 
polyclonal rabbit anti–β-catenin antibody (1:600 dilution; BD Transduction 
Laboratories), and rabbit anti–cyclin D1 antibodies (1:200; Santa Cruz). 
















GJCSPCMBTUTXBT MFTT UIBO UIBU JO4IIUSFBUFE85NZPGJCSPCMBTUT
1śWFSTVT851WFSTVTVOUSFBUFE&QJNmmf1
WFSTVT4IIUSFBUFE85
Downloaded on September  6, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/40676
SFTFBSDIBSUJDMF
 The Journal of Clinical Investigation   http://www.jci.org   Volume 120   Number 6   June 2010
was performed with Diva Decloaker reagent (BIOCARE). Antigen-antibody 
complexes were detected with biotinylated goat anti-rabbit IgG (1:500 dilu-
tion; PerkinElmer), streptavidin–horseradish peroxidase, and diaminobenzi-
dine. IL-6 expression was detected using a goat anti-recombinant mouse IL-6 
antibody (1:50 dilution; R&D systems) followed by a biotinylated donkey 
anti-goat antibody (1:500 dilution; Jackson ImmunoResearch Laboratories), 
streptavidin–horseradish peroxidase, and diaminobenzidine.
LPS stimulation of myofibroblasts. Epim–/– and WT colon myofibroblasts 
were seeded at a density of 2 × 105 cells per well in 6-well plates and grown 
to 85% confluence. Cultured myofibroblasts were incubated with LPS (2.5, 
5, and 10 μg/ml in serum-free media) for 6 hours (List Biological Labora-
tories Inc.). Based on this dose response, cells were incubated for 24 hours 
with LPS (5 μg/ml). Supernatant was collected for ELISA. Cells were har-
vested for RNA and protein for qRT-PCR and ELISA as described above 
and in Supplemental Methods. qRT-PCR data was expressed as fold induc-
tion relative to untreated samples.
Resident peritoneal macrophage isolation. Resident peritoneal macrophages 
were isolated by flushing the peritoneal cavity with cold PBS as described pre-
viously (35, 36, 60). Cells were counted for viability by trypan blue exclusion; 
plated (5 × 105 cells/well) in a 96-well plate in RPMI 1640 media (BioWhittak-
er) with 2 mM L-glutamine (Life Technologies), 10 mM HEPES, 1 mM sodium 
pyruvate (BioWhittaker), 50 U/ml penicillin and 50 mg/ml streptomycin (Life 
Technologies), 50 mM 2-ME (Fisher Scientific), and 10% FCS (HyClone); and 
cultured at 37°C in 5% CO2. After 24 hours, supernatants were collected for 
determination of IL-6 secretion by ELISA (Supplemental Methods).
Generation of bone marrow–derived dendritic cells. Dendritic cells were gen-
erated from mouse bone marrow progenitors as described previously (61). 
Bone marrow cells were harvested from femurs of Epim–/– and WT mice 
(n = 2) and cultured in 6-well plates with GM-CSF (10 ng/ml) and IL-4 
(0.3 ng/ml) in RPMI 1640 media supplemented as described above. Media 
containing GM-CSF and IL-4 was replaced on days 3 and 6 of culture. On 
day 7, cells were harvested; a portion was evaluated by flow cytometry to 
confirm the generation of dendritic cells. Remaining dendritic cells were 
plated in 96-well plates (5 × 105 cells/well) and treated with LPS (1 mg/ml) 
for 24 hours. Cells were harvested for RNA isolation, and supernatant was 
collected for evaluation of IL-6 secretion by ELISA.
SHH signaling in myofibroblasts. Epim–/– and WT colon myofibroblasts were 
seeded at a density of 2 × 105 cells/well in 6-well plates and grown to 85% 
confluence. Cells were incubated with recombinant mouse SHH aminoter-
minal peptide (0.9 μg/ml; R&D Systems) diluted in serum-free media; after 
24 hours, cells were harvested, and RNA was isolated for qRT-PCR.
Myofibroblast–Caco-2 coculture experiments. Epim–/– and WT colon myofi-
broblasts were plated as previously described (ref. 18; 1 × 106 cells/well) 
and cultured for 3 days in 6-well plates (Costar Corning Inc). Caco-2 cells 
were seeded on top of subconfluent layers of myofibroblast cells (3 × 105 
cells/well). To assess adherence of the Caco-2 cells to the Epim–/– and WT 
myofibroblasts, media was collected at 24 and 72 hours after plating, and 
cells were counted; no differences in cell adherence were found (n = 2 exper-
iments). Cocultures were examined daily by inverted phase microscopy, 
and photomicrographs were taken on day 4 after plating. To quantify dif-
ferences in Caco-2 colony size and assess morphology, photomicrographs 
were taken from 4 quadrants per well. The diameter of each Caco-2 colony 
was measured using Axiovision software (Zeiss). After 7 days, cocultures 
were fixed in paraformaldehyde and processed for histology.
Chordin (2 μg/ml; R&D Systems) was added to media immediately after 
Caco-2 cells were seeded and again on day 3 of coculture. Morphology and 
colony diameters were measured on day 4 as described above.
Electron microscopic analysis. Epim–/– and WT colon myofibroblasts were 
grown to confluence in T25 flasks (n = 2 independent experiments), 
harvested with trypsin/EDTA, fixed with 2.5% glutaraldehyde, and pro-
cessed for electron microscopy by the Electron Microscopy Core, Wash-
ington University School of Medicine. A total of 20 Epim–/– cells and 15 
WT cells were observed at ×3,000 and ×4,400 magnification, and images 
were obtained from several quadrants of each section. Nuclear/cytoplasmic 
ratio, nuclear membrane regularity and roundness, cytoplasmic membrane 
complexity, length of the rough ER, and mitochondria were evaluated in 
a semiquantitative manner, using magnification prints and a transparent 
0.2-cm grid. A total of 48 prints were scored. The state of dilation of the 
short stacks of rough ER was assessed for 16 Epim–/– and 11 WT cells. Each 
cell was divided into 4 quadrants. The width of 3–5 stacks of rough ER in 
each quadrant was measured using the transparent grid, and the average 
width of rough ER was calculated for each quadrant. Images were indepen-
dently reviewed by a pathologist blinded to the genotype.
Statistics. Data comparing Epim–/– and WT mice are presented as mean ± 
SEM, and significance was analyzed by 2-tailed Student’s t test (Microsoft 
Excel; Microsoft). P values less than or equal to 0.05 were considered sig-
nificant. Mortality rates were compared in Epim–/– and WT mice using the 
Fisher exact probability test (Vasserstats).
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